Does intravenous DX-9065a have acceptable tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers?
Intravenous DX-9065a, a novel factor Xa inhibitor, shows predictable linear pharmacokinetics and prolongs coagulation time without increasing bleeding time in healthy volunteers.
OBJECTIVE: The aim of this study was to assess the tolerability, pharmacokinetic and pharmacodynamic properties of DX-9065a, a novel low-molecule specific factor Xa inhibitor in healthy male volunteers. METHODS: DX-9065a was intravenously administered to healthy male Japanese volunteers at doses of 0.625 to 30 mg. The drug concentrations in plasma and urine were measured and pharmacokinetic parameters were calculated. Coagulation time and bleeding time were also measured. RESULTS: No serious adverse event was observed during or after administration of DX-9065a. The pharmacokinetics of DX-9065a in human subjects after intravenous dosing was linear. The simulated plasma concentrations of DX-9065 were well in accordance with the observed values. Though prolongation of coagulation times was dependent on plasma concentration of DX-9065, bleeding time did not increase even at the highest plasma concentration of 1640 ng/mL. CONCLUSIONS: DX-9065a had a good correlation between linear pharmacokinetics and pharmacodynamics after intravenous administration in humans.
Murayama et al. (1999) studied this question.